论文部分内容阅读
目的分析大剂量甲氨蝶呤(HD-MTX)联合利妥昔单抗治疗原发性中枢神经系统淋巴瘤(PCNSL)的效果。方法选取濮阳市安阳地区医院血液科2008年5月—2013年5月收治的28例PCNSL患者,按照随机数字表法将其分为试验组和对照组,各14例。试验组给予HD-MTX联合利妥昔单抗治疗,对照组给予HD-MTX联合全脑放疗治疗,比较两组的临床治疗效果。结果试验组与对照组总有效率分别为85.7%、50.0%,中位生存期(OS)分别为24个月、16个月,差异有统计学意义(P<0.05)。结论 HD-MTX联合利妥昔单抗治疗PCNSL,疗效显著。
Objective To analyze the effect of high-dose methotrexate (HD-MTX) combined with rituximab in the treatment of primary central nervous system lymphoma (PCNSL). Methods 28 patients with PCNSL who were admitted to Department of Hematology, Anyang Hospital, Puyang City from May 2008 to May 2013 were divided into experimental group and control group according to the random number table method, with 14 cases in each group. The experimental group was treated with HD-MTX combined with rituximab, while the control group was given HD-MTX combined with whole brain radiotherapy. The clinical effects of the two groups were compared. Results The total effective rates of the experimental group and the control group were 85.7% and 50.0%, respectively. The median survival time (OS) was 24 months and 16 months respectively. The difference was statistically significant (P <0.05). Conclusion HD-MTX combined with rituximab treatment of PCNSL, a significant effect.